Company news
Onconetix, Inc. (NASDAQ:ONCO) news
Every Onconetix, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
September 14, 2026
Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
September 14, 2026
Onco360® Has Been Selected as Part of an Ultra-Narrow Specialty Pharmacy Network for MIMRYLO™ (rusfertide)
September 9, 2026
Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live ...
September 3, 2026
OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors
August 17, 2026
Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG
August 5, 2026
Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District
June 24, 2026
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
May 19, 2026
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
May 13, 2026
Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson
April 9, 2026
Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phas...
April 7, 2026
Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update
April 2, 2026
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors
March 31, 2026
Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial Demonstration
March 25, 2026
Onconetix, Inc. Announces 1-for-5 Reverse Stock Split
March 23, 2026
Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company
February 12, 2026
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger A...
September 26, 2025
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
September 26, 2025
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagen...
September 22, 2025
Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement
July 16, 2025
Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel
June 16, 2025
Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders
June 11, 2025
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
May 22, 2025
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
April 8, 2025
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
March 24, 2025
Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Associ...
March 19, 2025
Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders
December 19, 2023
Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™
December 18, 2023
Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company
November 2, 2023
Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)
November 1, 2023
Blue Water Biotech Issues Letter to Shareholders
October 30, 2023
Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
October 10, 2023
Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q
August 28, 2023
Blue Water Biotech and Copay Consultants Collaborate to Build Copay Assistance Programs for Blue Water’s Commercial Products
August 10, 2023
Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds
August 1, 2023
Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians
July 31, 2023
Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®
July 25, 2023
Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities
July 17, 2023
Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support
July 11, 2023
Blue Water Biotech Teams with BFW Advertising to Market and Advertise Commercial Product Portfolio
July 6, 2023
Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products
July 6, 2023
Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particl...
June 28, 2023
Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio
June 21, 2023
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
June 14, 2023
Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 12, 2023
Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY
May 10, 2023
Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer
April 26, 2023
Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Trea...
April 25, 2023
Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnolo...
April 24, 2023
Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset
April 20, 2023